Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZhongtao YuanLLLin LiuYLYu Li

Discussion

Loading...

Member takes

Overview

Phase I trial shows GPRC5D CAR-T therapy achieves 100% response in refractory myeloma patients, suggesting a new treatment avenue.

Key Points

  • This research investigates the safety and efficacy of GPRC5D targeting CAR-T cell therapy in multiple myeloma patients.
  • Phase I clinical trial with dose-escalation design
  • 17 R/R multiple myeloma patients enrolled
  • Patients treated with standard or fast-GPRC5D CAR-T cells
  • All subjects received lymphodepletion regimens prior to CAR-T infusion
  • Safety profiles and clinical responses were evaluated.
  • Overall response rate (ORR) was 92.3% for standard CAR-T and 100% for fast-CAR-T
  • 61.5% of standard treatment patients achieved complete response (CR)
  • No dose-limiting toxicities observed
  • Most common adverse effects were hematological toxicities
  • Grade 1 cytokine release syndrome (CRS) was seen in all patients.

Cite This Study

Yuan et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6dehttps://doi.org/10.1182/blood-2025-5854
View Full Paper
Ask AI
Bookmark
Share